Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 839

MOTION in Limine No. 6: Exclude Reference to Amgen's Request for Injunctive Relief by Amgen Inc..(Gottfried, Michael)

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 839

Case 1:05-cv-12237-WGY

Document 839

Filed 08/20/2007

Page 1 of 4

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS AMGEN INC., Plaintiff, v. F. HOFFMANN-LAROCHE LTD., ROCHE DIAGNOSTICS GMBH, AND HOFFMANN LAROCHE INC., Defendants. ) ) ) ) ) ) ) ) ) ) )

Civil Action No.: 05 Civ. 12237 WGY

PLAINTIFF AMGEN'S MOTION IN LIMINE NO. 6: EXCLUDE REFERENCE TO AMGEN'S REQUEST FOR INJUNCTIVE RELIEF Pursuant to FRE 402 and 403, Plaintiff Amgen Inc. ("Amgen") requests that this Court preclude Defendants F. Hoffmann-La Roche Ltd., Roche Diagnostics GmbH, and Hoffmann-La Roche Inc. (collectively "Roche") from referring to the fact that Amgen is seeking injunctive relief in this case and any alleged implication or effect of awarding injunctive relief, including alleged negative impacts on consumer choice, the pharmaceutical market, or patient health. Amgen is seeking injunctive relief in this case, as is its right under 35 U.S.C. § 283. Because the issue of an injunction is not relevant to any issue to be decided by the jury, all references to Amgen's requested injunction should be excluded from the jury's hearing under FRE 402. Furthermore, if the possibility of injunctive relief is mentioned to the jury, it is likely to confuse or mislead the jury into deciding the infringement, validity or enforceability questions on nonlegal bases and should be excluded under FRE 403. It is likely that the jury would consider the implications of Amgen obtaining its injunctive relief, such as limiting consumer choice or supply, thus negatively affecting patients. For

Dockets.Justia.com

Case 1:05-cv-12237-WGY

Document 839

Filed 08/20/2007

Page 2 of 4

these reasons, Amgen moves to preclude any argument, evidence or other reference to the fact that Amgen is seeking injunctive relief during the proceedings before the jury. Amgen requests that this Court exclude any Roche argument or evidence concerning (a) the fact that Amgen is seeking injunctive relief; and (b) any alleged implication or effect of awarding injunctive relief, including alleged negative impacts on consumer choice, the pharmaceutical market, or patient health, as irrelevant under FRE 402 and substantially confusing and prejudicial under FRE 403. In support of this motion, Amgen submits a brief.

2

Case 1:05-cv-12237-WGY

Document 839

Filed 08/20/2007

Page 3 of 4

Respectfully Submitted, Date: August 20, 2007 AMGEN INC., By its attorneys, /s/ Michael R. Gottfried D. DENNIS ALLEGRETTI (BBO#545511) MICHAEL R. GOTTFRIED (BBO#542156) PATRICIA R. RICH (BBO#640578) DUANE MORRIS LLP 470 Atlantic Avenue, Suite 500 Boston, MA 02210 Telephone: [phone] Facsimile: [phone] LLOYD R. DAY, JR. (pro hac vice) DAY CASEBEER MADRID & BATCHELDER LLP 20300 Stevens Creek Boulevard, Suite 400 Cupertino, CA 95014 Telephone: [phone] Facsimile: [phone] WILLIAM GAEDE III (pro hac vice) McDERMOTT WILL & EMERY 3150 Porter Drive Palo Alto, CA 94304 Telephone: [phone] Facsimile: [phone] KEVIN M. FLOWERS (pro hac vice) MARSHALL, GERSTEIN & BORUN LLP 233 South Wacker Drive 6300 Sears Tower Chicago IL 60606 Telephone: [phone] Facsimile: [phone]

Of Counsel: STUART L. WATT WENDY A. WHITEFORD MONIQUE L. CORDRAY DARRELL G. DOTSON KIMBERLIN L. MORLEY ERICA S. OLSON AMGEN INC. One Amgen Center Drive Thousand Oaks, CA 91320-1789 [phone]

3

Case 1:05-cv-12237-WGY

Document 839

Filed 08/20/2007

Page 4 of 4

CERTIFICATE PURSUANT TO LOCAL RULE 7.1 I certify that counsel for the parties have conferred in an attempt to resolve or narrow the issues presented by this motion and no agreement was reached. /s/ Michael R. Gottfried Michael R. Gottfried

CERTIFICATE OF SERVICE I hereby certify that this document filed through the Electronic Case Filing (ECF) system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as nonregistered participants, on the above date. /s/ Michael R. Gottfried Michael R. Gottfried